AP NEWS

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 18, 2018

DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

According to the recently published report ‘5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2018’; 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Scope

The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Companies Featured

Acorda Therapeutics Inc. Adamed Sp z oo Avineuro Pharmaceuticals Inc. Celon Pharma SA H. Lundbeck AS Reviva Pharmaceuticals Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2dzwqv/5hydroxytryptamin?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005554/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/18/2018 08:18 AM/DISC: 09/18/2018 08:18 AM

http://www.businesswire.com/news/home/20180918005554/en

AP RADIO
Update hourly